Hsinchu, Taiwan

Chun-Jen Ting

This inventor holds 1 USPTO granted patent. Top assignee: Academia Sinica. Active years: 2005.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Inventor Chun-Jen Ting

Introduction: Chun-Jen Ting is a prominent inventor based in Hsinchu, Taiwan, known for his contributions to the field of immunology. With a patent to his name, Chun-Jen's work stands at the intersection of biotechnology and medicine, showcasing his innovative spirit and dedication to scientific advancement.

Latest Patents: Chun-Jen Ting holds a patent for "Peptide repeat immunogens," which relates to a polypeptide consisting of a receptor binding domain of exotoxin A, alongside at least two copies of a specific peptide sequence. This invention aims to enhance immune responses, potentially leading to improved vaccine development.

Career Highlights: Chun-Jen currently works at Academia Sinica, a leading research institution in Taiwan, where he collaborates with top-tier scientists and researchers. His efforts in the field have not only resulted in patents but have also contributed to advancing the understanding of immunogenic materials.

Collaborations: In his career, Chun-Jen Ting has had the opportunity to work alongside notable colleagues, including Jaulang Hwang and Chia-Tse Hsu. These collaborations highlight the importance of teamwork in the sphere of scientific research and innovation.

Conclusion: Chun-Jen Ting's inventive contributions, particularly his patent on peptide repeat immunogens, underline the significance of research and development in healthcare. As he continues his work at Academia Sinica, his innovations may pave the way for future breakthroughs in immunology, showcasing the impactful role of inventors in scientific advancement.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…